US-Based Deep Learning Model for Differentiating Hepatocellular Carcinoma (HCC) From Other Malignancy in Cirrhotic...

The aim was to build a predictive model based on ultrasonography (US)-based deep learning model (US-DLM) and clinical features (Clin) for differentiating hepatocellular carcinoma (HCC) from other malignancy (OM) in cirrhotic patients. 112 patients with 120 HCCs and 60 patients with 61 OMs were included. They were randomly divided into training and test cohorts with a 4:1 ratio for developing and evaluating US-DLM model, respectively. Significant Clin predictors of OM in the training cohort were combined with US-DLM to build a nomogram predictive model (US-DLM+Clin). The diagnostic performance of US-DLM and US-DLM+Clin were compared with that of contrast enhanced magnetic resonance imaging (MRI) liver imaging and reporting system category M (MRI LR-M). US-DLM was the best independent predictor for evaluating OMs, followed by clinical information, including high cancer antigen 199 (CA199) level and female. The US-DLM achieved an AUC of 0.74 in the test cohort, which was comparable with that of MRI LR-M (AUC=0.84, p=0.232). The US-DLM+Clin for predicting OMs also had similar AUC value (0.81) compared with that of LR-M+Clin (0.83, p>0.05). US-DLM+Clin obtained a higher specificity, but a lower sensitivity, compared to that of LR-M +Clin (Specificity: 82.6% vs. 73.9%, p=0.007; Sensitivity: 78.6% vs. 92.9%, p=0.006) for evaluating OMs in the test set. The US-DLM+Clin model is valuable in differentiating HCC from OM in the setting of cirrhosis.